Investor: Danish biotech is either glorified or it disappears
One thing is of special importance if Danish biotech wants to shed its label as a “loser business”, says a long-time investor in the biopharma industry. But the dream of a glorified sector is still alive.
BY BENJAMIN WERNER CHRISTENSEN
Danish biotech has a lousy image, but according to major investor Florian Schönharting, who has invested huge sums in both Danish and international biopharma through his company NB Capital, there is a perfectly good explanation for that. In this interview with MedWatch he explains how he sees the development in the Danish biotech companies formed around the turn of the century and offers his view on what it will take for the industry to shed its poor reputation.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
“I‘m certainly not bitter, but maybe a bit disappointed”
For abonnenter
”Investors are much more cynical today”
For abonnenter
